# Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

> **NCT02145715** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Prof Jamie Cavenagh** · enrollment: 54 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT02145715
- **Lead sponsor:** Prof Jamie Cavenagh
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2015-07
- **Final completion:** 2016-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2015-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145715, "Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02145715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*